Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib-Reference-Cited by-同舟云学术

Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib

Published:2024-07-19 Issue: Volume: Page:
ISSN:2768-6566
Container-title:JEADV Clinical Practice
language:en
Short-container-title:JEADV Clinical Practice

Author:

Malkovics Tamás¹²^ORCID,Horváth Orsolya N.³,Sárdy Miklós¹³^ORCID

Affiliation:

1. Department of Dermatology, Venereology, and Dermatooncology Semmelweis University Budapest Hungary

2. Rácz Károly Doctoral School of Clinical Medicine, Semmelweis University Semmelweis University Budapest Hungary

3. Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany

Abstract

AbstractBoth bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases that can be challenging to treat in individual cases. Janus kinase inhibitors have shown efficacy in several autoimmune and inflammatory diseases, although these drugs are not yet widely used in autoimmune bullous diseases. We report two recalcitrant cases of pemphigoid with mucous membrane involvement which were successfully treated with the JAK 1/2 inhibitor baricitinib after all other feasible therapeutic options had been exhausted.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.511

Reference11 articles.

1. Bullous pemphigoid

2. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I

3. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II

4. Effective treatment of refractory lichen planus pemphigoides with a Janus kinase-1/2 inhibitor

5. Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate